Free access to this special issue has been made possible by the financial support of the 1st Annual Treatment as Prevention (TasP) Workshop, held May 4-6, 2011 in Vancouver, British Columbia (BC), Canada. The Workshop was organised and hosted by the BC Centre for Excellence in HIV/AIDS and co-hosted by the International AIDS Society, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the World Health Organization and the National Institute on Drug Abuse. Co-sponsors include the National Institutes of Health Office of AIDS Research, the National Institute of Allergy and Infectious Diseases, the United States President’s Emergency Plan for AIDS Relief (PEPFAR), the Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS), the Bill & Melinda Gates Foundation, the Canadian Institutes for Health Research and the Public Health Agency of Canada.
Academic partners included the University of British Columbia, Simon Fraser University, Vancouver Coastal Health Authority and Providence Health Care, Vancouver. Industry sponsors included Bristol- Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. Additional Industry supporters included Abbott Laboratories and Biolytical.